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WHAT IS NEW ? 1 
 The intravascular ultrasound results of the SCHEDULE trial demonstrate that 2 
everolimus initiation and total early cyclosporine elimination significantly reduces the 3 
progression of cardiac allograft vasculopathy (CAV) at 12 and 36 months compared 4 
to patients treated with standard cyclosporine therapy. 5 
 The early use of everolimus with total elimination of cyclosporine is safe as 6 
demonstrated by similar cardiac function and low mortality in both treatment groups. 7 
 Virtual Histology analysis confirmed that this immunosuppressive approach is not 8 
associated with any significant increase in inflammatory tissue components (calcified 9 
and necrotic tissue) or systemic inflammatory markers.  10 
 11 
WHAT ARE THE CLINICAL IMPLICATIONS ? 12 
 There is currently no effective medical therapy for CAV after HTx. Everolimus and 13 
total early cyclosporine elimination had a beneficial effect on CAV progression after 14 
HTx and such therapy could potentially improve long-term outcome after HTx.  15 
 Everolimus initiation and total early cyclosporine elimination does not appear to have 16 
any detrimental effect on CAV morphology or immune marker activity. This 17 
immunosuppressive protocol also has an additional beneficial effect on renal function 18 







Background: Cardiac allograft vasculopathy (CAV) limits survival after heart transplantation 3 
(HTx) and the effect of different immunosuppressive regimens on CAV is not fully 4 
understood. The randomized SCHEDULE (Scandinavian heart transplant everolimus de-5 
novo study with early calcineurin inhibitors avoidance) trial evaluated whether initiation of the 6 
proliferation signal inhibitor everolimus and early cyclosporine elimination can reduce CAV 7 
development. 8 
Methods and Results: The SCHEDULE trial was a multicenter Scandinavian trial where 115 9 
de-novo HTx recipients were randomized to everolimus with complete cyclosporine 10 
withdrawal 7-11 weeks after HTx or standard cyclosporine-based immunosuppression. 76 11 
(66%) patients had matched intravascular ultrasound (IVUS) examinations at baseline, 12 12 
months and 36 months. IVUS analysis evaluated maximal intimal thickness (MIT), percent 13 
atheroma volume (PAV) and total atheroma volume (TAV). Qualitative plaque analysis using 14 
Virtual Histology assessed fibrous, fibrofatty and calcified tissue as well as necrotic core. 15 
Serum inflammatory markers were measured in parallel.  16 
The everolimus group (n=37) demonstrated significantly reduced CAV progression as 17 
compared to the cyclosporine group (n=39) at 36 months [∆MlT 0.09±0.05 versus 0.15±0.16 18 
mm (p=0.03), ∆PAV 5.3±2.8% versus 7.6±5.9 (p=0.03), ∆TAV 33.9±71.2 mm3 versus 19 
54.2±96.0 mm3 (p=0.34), respectively]. At 36 months the number of everolimus patients with 20 
rejection graded ≥2R was 15 (41%) as compared to 5 (13%) in the cyclosporine group 21 
(p=0.01). Everolimus did not affect CAV morphology or immune marker activity during the 22 
follow-up period. 23 
Conclusions: The SCHEDULE trial demonstrates that everolimus initiation and early 24 
cyclosporine elimination significantly reduces CAV progression at 12 months and this 25 
beneficial effect is clearly sustained at 36 months.  26 






Cardiac allograft vasculopathy (CAV) is reported to affect 50% of heart transplant (HTx) 2 
recipients within 5 years after transplantation 1 and is the second leading cause of post-HTx 3 
mortality 1. Prevention of CAV remains a significant clinical challenge as the widespread use 4 
of powerful immunosuppressive agents including calcineurin inhibitors (CNI), such as 5 
cyclosporine A (CsA) or tacrolimus, do not appear to ameliorate CAV development 2. In fact, 6 
the use of CNI agents is associated with adverse effects including metabolic disturbances 7 
(e.g. new onset diabetes) and renal toxicity 3 which may negatively influence CAV 8 
development 4. An alternative immunosuppressive protocol providing sufficient immune 9 
modulation without such adverse effects and with potential attenuating effects on CAV 10 
development is, therefore, an ideal but elusive goal in HTx.  11 
During the last decade, immunosuppressive drugs inhibiting the mammalian target of 12 
rapamycin (mTOR) signaling pathway have received considerable attention. Everolimus is an 13 
mTOR inhibitor that arrests the cell cycle of lymphocytes and vascular smooth cells in the G1 14 
phase 5 and this combined immunosuppressive and antiproliferative effect is relevant to CAV 15 
development. It has previously been demonstrated that everolimus initiation in de-novo HTx 16 
recipients with standard or reduced CNI therapy can attenuate intimal thickening of coronary 17 
arteries 6-8. We demonstrated in the 12-month SCHEDULE study that de-novo everolimus 18 
therapy and early elimination of CNI therapy is also feasible and reduces the early 19 
progression (i.e. 12 months) of CAV 9. Furthermore, such a CNI-free strategy is associated 20 
with improved renal function at 12 months 10 and a beneficial effect on renal function and 21 
coronary artery intimal thickness is maintained at 36 months11. 22 
The purpose of the current report of the SCHEDULE trial is to provide an in-depth 23 
evaluation of the effect of everolimus initiation and CNI elimination on CAV at 36 months by 24 
utilizing percent atheroma volume (PAV) and total atheroma volume (TAV) as alternative 25 
endpoints to MIT as well as angiographic data. Inflammatory marker measurement was also 26 




mediate any observed intimal changes associated with everolimus therapy. Finally, the 1 
current report also provides qualitative assessment of plaque morphology by Virtual 2 































 METHODS 1 
Patient population  2 
A detailed description of the SCHEDULE trial has been reported previously 10). In brief, the 3 
SCHEDULE trial was a 12-month prospective, open-label, multicenter, randomized controlled 4 
study undertaken at five HTx centers in Scandinavia. Adult de-novo HTx recipients were 5 
randomized in a 1:1 ratio to: (i) low dose everolimus, low-dose cyclosporine, mycophenolate 6 
mofetil (MMF) and corticosteroids with elimination of cyclosporine and step up to full-dose 7 
everolimus after 7-11 weeks or (ii) conventional treatment with cyclosporine, MMF and 8 
corticosteroids. All patients received the first dose of everolimus, cyclosporine, MMF, and 9 
corticosteroids no later than the fifth postoperative day. The current report is 36-month 10 
continuation of the original SCHEDULE study evaluating CAV progression. The first 11 
SCHEDULE visit was performed in December 2009 and the final month 36 follow-up visit 12 
took place in November 2014. Written informed consent was obtained from all patients. The 13 
study was approved by the regional ethical authority in each country and was carried out in 14 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, 15 
applicable local regulations and the Declaration of Helsinki and was registered with 16 
ClinicalTrials.gov (NCT01266148). Because of the sensitive nature of the data collected for 17 
this study, requests to access the dataset from qualified researchers trained in human 18 
subject confidentiality protocols may be sent to the corresponding author and will be subject 19 
to approval from the steering committee.  20 
IMMUNOSUPPRESSIVE MEDICATION 21 
All patients received induction treatment with antithymocyte globulin (ATG, Thymoglobulin®, 22 
Genzyme Corporation, Cambridge, MA) within 12 hours of HTx and this continued for up to 23 
five days. In the everolimus group, everolimus was initiated at a dose of 0.75 mg twice daily 24 
no later than the fifth postoperative day and cyclosporine elimination took place at week 7 25 




be postponed up to week 11. All patients received statin therapy and patients who were 1 
seronegative for cytomegalovirus (CMV) and received a graft from a CMV-positive donor 2 
were given prophylaxis with oral valganciclovir for at least three months according to the 3 
local protocol. 4 
IVUS imaging  5 
 6 
The SCHEDULE trial protocol specified IVUS examination of the same major epicardial 7 
coronary artery (preferentially the left-anterior descending coronary artery) and this was 8 
conducted while performing coronary angiography at week 7–11, 12 months and 36 months 9 
post-HTx using a 20 MHz, 2.9F, monorail electronic Eagle Eye Gold IVUS catheter (Volcano 10 
Corporation Inc, CA, USA). Patients with severe renal impairment (as judged by the principal 11 
investigator but generally considered as GFR < 30 ml/min/1.72 m2) were to be excluded from 12 
IVUS study (due to the risk of angiographic contrast) but no patients had this level of renal 13 
impairment and, hence, this exclusion criterion did not apply to any of the randomized 14 
patients. IVUS images were acquired at a rate of 30 frames/sec and pullback speed of 0.5 15 
mm/sec. Images were stored digitally for off-line analysis conducted after trial closure by a 16 
core laboratory (Oslo University Hospital, Rikshospitalet, Oslo, Norway) blinded to patient 17 
treatment. IVUS analysis was performed according to the guidelines for acquisition and 18 
analysis of IVUS images by the American College of Cardiology and European Society of 19 
Cardiology 12. Precise matching of the IVUS recordings was performed followed by contour 20 
detection of both the lumen and external elastic membrane (EEM) at approximately 1 mm 21 
intervals using validated software (QIVUS, v.3.0, Medis medical imaging systems, Leiden, 22 
the Netherlands).  23 
 24 
Greyscale IVUS analysis 25 
 26 
Maximal intimal thickness (MIT) is an established predictor of all-cause mortality, myocardial 27 




MIT between matching segments at baseline and 12 and 36 months was utilized as the 1 
primary greyscale IVUS efficacy variable. Other secondary IVUS variables were: (i) percent 2 
atheroma volume (PAV) which expresses the summation of atheroma areas in proportion to 3 
the EEM area using the equation: PAV = ∑ (EEMarea – Lumenarea)/∑EEMarea) x 100 (ii) 4 
normalized total atheroma volume (TAV) and (iii) incidence of CAV (defined as mean MIT 5 
≥0.5 mm over the entire matched segment). The mean length of analyzed segments at 6 
baseline, 12 months and 36 months was 36.7±7.3 mm, 36.4±8.1 and 36.8±10.5 mm, 7 
respectively.  8 
 9 
Angiographic assessment of CAV 10 
 11 
Coronary artery angiogram data was evaluated by experienced local staff blinded to 12 
treatment and was reported according to the International Society for Heart and Lung 13 
Transplantation standardized nomenclature for CAV15.  14 
 15 
Virtual histology analysis 16 
 17 
 18 
Virtual Histology (Volcano Corporation Inc, Rancho Cordova, CA) is a technological tool that 19 
utilizes backscatter radiofrequency data obtained during IVUS pullback for qualitative plaque 20 
assessment. VH-IVUS possesses 94–97% ex-vivo and 87–97% in-vivo accuracy for 21 
characterization of basic tissue components 16,17. VH-IVUS data obtained at baseline, 12 and 22 
36 months was analyzed with validated software (QIVUS, v.3.0, Medis medical imaging 23 
systems, Leiden, the Netherlands) that reconstructs tissue maps with four identifiable major 24 
components (fibrous, fibrofatty, dense calcified and necrotic core components) based on 25 
mathematical autoregressive spectral analysis of backscattered radiofrequency data. The 26 









Inflammatory marker analysis 1 
In total, 65 patients (from two centers), underwent plasma sampling by standard 2 
venipuncture at baseline, 12 and 36 months. Plasma levels of vascular cell adhesion 3 
molecule 1 (VCAM-1), intercellular adhesion molecule 1(ICAM-1), the CXC chemokine 4 
CXCL16 and soluble tumor necrosis factor receptor (sTNFR)-1 were measured by enzyme 5 
immunoassays (EIA) (R&D Systems, Minneapolis, MN). Plasma levels of C-reactive protein 6 
(CRP) and von Willebrand factor (vWf) were measured by EIAs as previously described 18. 7 
All intra-assay and inter-assay coefficients of variance were <10%.  8 
 9 
Statistical analysis 10 
 11 
Analyses were performed with the SPSS v 22.0 statistical software (SPSS Inc. Chicago, IL). 12 
Data is expressed as mean±SD and a two-tailed p-value <0.05 was considered statistically 13 
significant. Baseline characteristics were compared using Student’s t-test, Mann-Whitney test 14 
and Pearson’s chi-square  test as appropriate. Pearsons’ chi-square test was used to 15 
compare the incidence of acute rejection and Cochran–Mantel–Haenszel test was utilized to 16 
compare the 36-month incidence of CAV in the treatment groups (adjusted for baseline 17 
CAV). Changes in IVUS endpoints were compared between treatment groups by performing 18 
analysis of covariance (ANCOVA) with the baseline IVUS value included as a covariate and 19 
treatment group as a fixed factor. ANCOVA p-values represent between group contrast. 20 
Multivariate regression analysis was performed to identify predictors of CAV progression 21 
following an initial exploratory univariate analysis that selected potentially relevant covariates 22 
(p-value <0.05). Multivariable regression analysis was performed using the forward stepwise 23 
method with criteria for entry and exit at p <0.05 and <0.10, respectively. Change in 24 
inflammatory marker values were compared between treatment groups by ANCOVA analysis 25 








PATIENT POPULATION 3 
Of the 115 patients randomized in the SCHEDULE study, 76 (66%) patients had matching 4 
IVUS recordings at baseline, 12 and 36 months with a similar number between both 5 
treatment groups (39 everolimus versus 37 controls, Figure 1). Fifty-one (44%) patients had 6 
matching VH-IVUS recordings at these three timepoints. Overall, 10 (9%) patients died 7 
during the 36 month follow-up period. There were 7 deaths in the cyclosporine group with 8 
cause of death recorded as cerebrovascular accident, sepsis, cardiac arrest, sudden death, 9 
graft loss and 2 cases of malignancy. There were 3 deaths in the everolimus group with 10 
cause of death recorded as graft failure, pleural hemorrhage and malignancy.   11 
Mean age of patients in the 36-month IVUS study population was 50.8±12.1 years 12 
and there was no significant difference in baseline characteristics between the treatment 13 
groups (Table 1). There was no significant difference in baseline characteristics when 14 
comparing the 76 IVUS patients with the total SCHEDULE population (n=115) (GFR in IVUS 15 
population was 59.7 mL/min/1.73 m2 as compared to 60.7 mL/min/1.73 m2 in the total 16 
SCHEDULE population (p=0.41) - remaining data not shown).  17 
IMMUNOSUPPRESSION 18 
All patients in the everolimus group discontinued cyclosporine at week 7–11 according to the 19 
trial protocol. The mean everolimus trough level at 12 and 36 months was 7.9±3.8 ng/mL and 20 
6.9±2.1 ng/mL, respectively. In the everolimus group, 6 (16%) patients resumed low-dose 21 
cyclosporine in combination with everolimus while 6 (16%) patients discontinued everolimus 22 
permanently due to adverse effects. Among the 39 control patients, 5 (13%) patients were 23 
switched from cyclosporine to everolimus therapy due to deteriorating renal function. There 24 





Acute rejection 1 
The incidence of biopsy proven acute rejection (BPAR) during the first 12 months was 78.4% 2 
in the everolimus group versus 56.4% in the cyclosporine group (p=0.14). The vast majority 3 
of rejection episodes ≥2R occurred during the first 12 months with only 7 episodes occurring 4 
in the 12-36 month period. These episodes occurred in 6 patients of whom 5 had previously 5 
experienced similar rejection episodes (≥2R) during the first 12 months. Overall, at 36 6 
months the number of patients with rejection graded ≥2R was 15 (41%) in the everolimus 7 
group as compared to 5 (13%) in the cyclosporine group (p=0.01). Rejection treatment 8 
consisted of corticosteroids in all cases without the need for cytolytic agents. No cases of 9 
humoral rejection or rejection with hemodynamic compromise were observed in the 36-10 
month IVUS study population.  11 
GREYSCALE IVUS OUTCOME 12 
Only patients with exact matching IVUS recordings at baseline, 12 and 36 months (n=76) are 13 
considered in the current IVUS report. As reported previously, greyscale IVUS at 12 months 14 
demonstrated that everolimus patients had a mean increase in MIT of 0.02±0.05 as 15 
compared to 0.08±0.11 mm amongst cyclosporine patients (p<0.01) (Figure 2). This effect of 16 
everolimus persisted at 36 months with a total mean increase in MIT of 0.09±0.05 as 17 
compared to 0.15±0.16 mm amongst cyclosporine patients (p=0.03 (36-month values 18 
compared to baseline), Figure 2). In the current study, a similar pattern was seen for PAV 19 
with a significantly smaller mean increase amongst everolimus patients (1.2±2.0 and 20 
5.3±2.8%) as compared to the cyclosporine group (3.7±4.1 and 7.6±5.9%) (12 [p<0.01] and 21 
36 [p=0.03] months, respectively) (Figure 2). In contrast, when considering normalized TAV 22 
the differences between the everolimus and cyclosporine group did not reach statistical 23 
significance. Thus the increase in total atheroma burden in everolimus patients was -24 




11.1±27.6 mm3 and 54.2.±96.0 mm3 in the cyclosporine group (p=0.08 and p=0.34, 1 
respectively) (Figure 2).  2 
The number of everolimus patients defined as having CAV (mean MIT ≥0.05 mm) 3 
increased from 12 (32%) at baseline to 16 (43.2%) at 36 months as compared to an increase 4 
from 10 (26%) to 21 (53.8%) patients in the cyclosporine arm (p=0.10 when analyzing 5 
differences in changes). Multivariable stepwise regression analysis was performed with the 6 
following five candidate variables: recipient age, donor age, everolimus, gender and diabetes 7 
mellitus. Of these variables recipient gender, donor age and treatment with everolimus were 8 
selected as independent predictors of CAV progression with everolimus having an 9 
independent adjusted treatment effect of B = -0.04 (95% CI -0.10-0.01) mm (p=0.03) (Table 10 
2). 11 
CMV infection/viremia did not influence CAV progression as evidenced by nearly 12 
identical disease progression in patients with and without CMV infection/viremia (ΔMIT, PAV 13 
and TAV at 36 months 0.12±0.13, 6.4±5.0 and 41.9±89.2 versus 0.12±0.13 mm, 6.5±5.0% 14 
and 59.2±65.4 mm3, respectively (all p-values >0.05).  15 
Per protocol greyscale IVUS analysis 16 
Analysis of greyscale IVUS recordings was also performed in the per protocol population, 17 
which excluded 17 patients (12 in the everolimus and 5 in cyclosporine arm) where treatment 18 
according to randomization arm was not followed. Mean increase in MIT at 36 months in the 19 
everolimus group was 0.09±0.05 mm as compared to 0.16±0.17 mm in the cyclosporine arm 20 
(p=0.04). ΔPAV and ΔTAV in everolimus patients was 4.9±2.8% and 15.9±47.3 mm3 as 21 
compared to 8.0±6.0% (p=0.02) and 59.3±101.0 mm3 (p=0.05) in the cyclosporine group, 22 
respectively. 23 
Angiographic assessment of CAV 24 
The number of everolimus patients with angiographic CAV increased from 4 (10.8%) (all 25 




increase from 5 (12.8%) at baseline (all CAV1) to 8 (20.5%) at 36 months (5 and 3 patients 1 
with CAV1 and CAV 2) in the cyclosporine arm (p=0.32). 2 
CAV progression at 36 months according to presence of donor disease  3 
When utilizing baseline mean MIT ≥ 0.50 mm as the threshold for defining donor disease 19 4 
(i.e. atherosclerosis) we noted that 54 patients (25 everolimus, 29 cyclosporine) did not have 5 
donor disease. There was a beneficial effect of everolimus in this subgroup of patients and 6 
mean ∆MIT at 36 months was 0.08±0.05 and 0.15±0.16 mm in the everolimus and 7 
cyclosporine group, respectively (p=0.04) (Figure 3). The alternative endpoint PAV confirmed 8 
a significant beneficial between the two treatment arms (∆PAV at 36 months 4.5±2.7 and 9 
7.7±6.1 mm in the everolimus and cyclosporine group, respectively), whereas TAV did not 10 
show a significant difference between the two groups (Figure 3). Amongst 22 patients with 11 
donor disease (12 everolimus and 10 cyclosporine) the three independent IVUS endpoints 12 
MIT, PAV and TAV demonstrated similar disease progression in both treatment groups 13 
(Figure 3). 14 
Virtual Histology analysis 15 
Virtual histology analysis of matched VH-IVUS recordings at baseline and 12 and 36 months 16 
revealed no significant difference in change in plaque morphology according to treatment 17 
group.  Overall, the increase in fibrotic, fibrofatty, calcified and necrotic tissue during the 36 18 
month period everolimus group was -7.4±12.8%, 9.6±10.9%, 0.0±8.4% and -2.6±9.1% in the 19 
everolimus group, as compared to 0.3±12.9%, 7.4±14.7%, -3.5±8.3% and -4.5±9.8% in the 20 
cyclosporine group, respectively (all p-values >0.05; Figure 4). 21 
Immune marker profile 22 
There was a significant decline in levels of all measured inflammatory markers from baseline 23 




(Table 3). A post-hoc analysis was performed to evaluate the change in inflammatory marker 1 
levels according to rapid CAV progression (Δ MIT ≥0.10 mm), but there was no evidence of a 2 
relationship between these biomarkers and increased CAV (data not shown). A separate 3 
post-hoc analysis found no significant difference in change in levels of inflammatory amongst 4 






The current follow-up of de-novo HTx recipients in the SCHEDULE trial has demonstrated 2 
that everolimus initiation and early CNI elimination reduces CAV progression at 12 months 3 
and this beneficial effect is sustained at 36 months. This immunosuppressive approach is 4 
safe as demonstrated by similar cardiac function and low mortality in both treatment groups, 5 
despite the difference in biopsy verified acute rejection rate 10,11. Furthermore, Virtual 6 
Histology analysis confirmed that everolimus initiation and CNI withdrawal is not associated 7 
with any significant increase in inflammatory tissue components (calcified and necrotic 8 
tissue) or systemic inflammatory markers.  9 
CAV is an important complication following HTx. Although CNI therapy is a pillar of 10 
current immunosuppressive protocols, the effect of such agents on CAV is limited and may 11 
potentially have a detrimental effect on disease progression 20. The mTOR inhibitor 12 
everolimus is an immunosuppressive agent with additional effects that could be of interest in 13 
relation to CAV (i.e., anti-proliferative and anti-fibrotic). Indeed, a beneficial effect of 14 
everolimus on CAV has been demonstrated in de-novo HTx recipients but not in 15 
maintenance recipients. The study by Eisen et al. 6 demonstrated that everolimus instead of 16 
azathioprine together with background CNI therapy reduces CAV amongst de-novo HTx 17 
recipients. Similarly, another trial evaluating CAV in the de-novo setting demonstrated a 18 
beneficial effect of everolimus and reduced CNI as compared to MMF and standard CNI 19 
therapy 7. In contrast, the NOCTET trial 21 amongst maintenance HTx recipients failed to 20 
demonstrate a beneficial effect of everolimus and reduced CNI therapy on CAV, although a 21 
beneficial effect was seen in those who received azathioprine but not in those receiving 22 
MMF. 23 
The SCHEDULE trial is the first to investigate the use of everolimus with early CNI 24 
elimination showing that this immunosuppressive approach significantly reduces CAV 25 
progression at 12 and 36 months. As reported previously, everolimus initiation and CNI 26 




the everolimus group 10,11. The association between early intimal thickening and adverse 1 
prognosis has previously been established amongst HTx recipients 13,14. Similarly, there is 2 
sizeable data indicating that declining renal function following HTx is associated with 3 
increased morbidity and mortality 4,22. Hence, everolimus initiation and early CNI elimination 4 
in de-novo HTx recipients seems to have a dual beneficial advantage on CAV and renal 5 
function that may have a positive and potential synergistic impact on long-term clinical 6 
outcome, although this remains to be demonstrated. 7 
Our post-hoc analysis of CAV progression according to the presence of donor 8 
disease revealed that everolimus only attenuates intimal thickening in patients without 9 
underlying donor disease. Everolimus was unable to influence progression of CAV in the 10 
setting of pre-existing donor disease. However, it should be noted that our study had a 11 
relatively younger donor age as compared to previous studies14 and, hence, this negative 12 
finding is based on a relatively small cohort of patients with donor disease. Despite the 13 
possibility of a type 2 error our results indicate the need to consider everolimus at the earliest 14 
possible timepoint following HTx. Our results suggest that a certain window of opportunity is 15 
likely to exist where everolimus has a beneficial effect on intimal thickening as supported by 16 
the NOCTET results 21 where everolimus did not influence CAV progression amongst 17 
maintenance recipients.   18 
Everolimus is a mTOR inhibitor that has been shown to possess both anti-proliferative 19 
and anti-fibrotic effect in addition to its immunomodulatory properties 23 and, hence, may 20 
have a qualitative effect on intimal thickening. The current study, however, demonstrated that 21 
everolimus does not significantly influence intimal tissue composition as compared with 22 
traditional immunosuppression. The proportion of inflammatory tissue components remained 23 
unchanged in both treatment groups and a similar pattern was also seen in markers of 24 
systemic inflammation. This neutral finding is in contrast to the previous NOCTET reporting 25 
increased inflammatory tissue in maintenance recipients treated with everolimus 21. Hence, 26 
the effect of everolimus on CAV in the current study is primarily manifested by the observed 27 




morphological changes (measured by Virtual Histology). Moreover, the beneficial effects of 1 
everolimus on CAV seem unrelated to its anti-inflammatory properties as a similar anti-2 
inflammatory effect was seen during CNI treatment both within the lesion and systemically.  3 
According to the SCHEDULE trial patients in the everolimus arm received both CNI 4 
and everolimus until week 7. We found no association between the measured systemic 5 
inflammatory markers and CAV progression. Nevertheless, it remains possible that the 6 
increased intensity of immunosuppression coupled with anti-lymphocyte induction during the 7 
early period had a positive influence on inflammation and CAV and should be explored 8 
further. The everolimus arm was noted to experience a significantly greater number of grade 9 
2R rejections and this could potentially mitigate a reduction in systemic inflammation 10 
attributable to everolimus. With reference to this, a post-hoc analysis found no significant 11 
difference in change in levels of inflammatory amongst everolimus patients with and without 12 
2R rejection episodes (all p-values >0.05) indicating that cellular rejection did not influence 13 
systemic markers of inflammation measured at 36 months.   14 
The current immune marker results are in contrast to previously reported studies 24-27 15 
demonstrating a clear association between these diverse makers and traditional 16 
atherosclerosis further supporting the notion that the pathophysiology of CAV is distinctly 17 
different from native atherosclerosis 28. Nonetheless, the neutral effect of everolimus in this 18 
study (de novo recipients) as compared with the increased inflammatory effect in the 19 
NOCTET study (maintenance HTx) further suggest that early intervention with everolimus is 20 
preferable.  21 
The present study has some limitations. Imaging of the left ascending artery was 22 
utilized used as a surrogate for all potential CAV that may be present. The number of 23 
patients was relatively small in certain sub-analyses including the evaluation of everolimus 24 
according to presence/absence of donor disease as well as assessment of systemic 25 
inflammatory markers particularly amongst patients with and without 2R rejection. 26 
Angiographic assessment of CAV did not reveal any benefit of everolimus but it should be 27 




The relative homogeneous study population in this Scandinavian cohort of predominantly 1 
male Caucasian patients should also be noted. Data regarding cause of death was 2 
available for all mortality cases but histology of the coronary arteries of these patients 3 
would have been beneficial.  Despite these limitations, the authors believe the data is 4 
robust and particularly relevant to clinical practice as it provides the longest CAV follow-up 5 
period to date amongst de-novo HTx patients treated with everolimus. 6 
In conclusion, this 36 month follow-up of the SCHEDULE trial has confirmed that the 7 
beneficial effect of everolimus on CAV at 12 months is maintained at 36 months. The benefit 8 
of everolimus was not evident amongst a small cohort of patients with established donor-9 
transmitted disease suggesting that early use of this agent is likely to be more effective. 10 
There is no evidence of everolimus having a detrimental effect on CAV morphology or 11 
immune marker activity during this follow-up period even if the number of grade 2R rejections 12 
was increased in the everolimus group. Given these positive findings, coupled with the 13 
beneficial effect of everolimus on renal function during the same follow-up period, it appears 14 
that everolimus and early CNI withdrawal is an attractive alternative immunosuppressive 15 
protocol that may improve long-term outcome after HTx. The beneficial effect of everolimus 16 
on CAV may involve anti-fibrotic and anti-proliferative effect, but at present it mechanisms of 17 




 Acknowledgements 1 
The authors are grateful to the SCHEDULE investigators, co-investigators and study nurses: 2 
Copenhagen, Lene Larsen; Aarhus: Else Marie Tram, Dorte Mølbak; Göteborg, Vilborg 3 
Sigurdardottir, Nedim Selimovic, Entela Bollano, Sven-Erik Bartfay, Smita Dutta Roy, Helena 4 
Rexius, Annie Janssen, Marita Rosenberg; Lund, Liselotte Persson, Susanne Nilsson, Björn 5 
Kornhall, Öyvind Reitan; Oslo: Anne Relbo, Ingelin Grov, Elisabeth Bjørkelund and Asgrimur 6 
Ragnarsson. 7 
Disclosures 8 
This trial was supported by Novartis Scandinavia. D Solbu is a previous employee of 9 
Novartis Scandinavia. Dr Dellgren is the sponsor and principal investigator of the ScanCLAD 10 
trial and is receiving a research grant from Astellas. The remaining authors have no conflicts 11 







FIGURE LEGENDS 2 
 3 
Figure 1. Patient disposition for the 36-month IVUS analysis.    4 
Figure 2. Progression of cardiac allograft vasculopathy in the two treatment arms as 5 
assessed by change in Maximal Intimal Thickness (MIT), Percent Atheroma Volume (PAV), 6 
and Total Atheroma Volume (TAV) at 12 and 36 months (values shown are change from 7 
baseline with statistical testing by ANCOVA analysis and p-value represents between group 8 
contrast).  9 
Figure 3. Progression of cardiac allograft vasculopathy in the two treatment arms stratified 10 
according to absence or presence of donor disease defined as baseline Maximal Intimal 11 
Thickness ≥0.5 mm (values shown are change from baseline with statistical testing by 12 
ANCOVA analysis and p-value represents between group contrast).  13 
Figure 4. Virtual histology tissue analysis with change in composition of fibrous-, fibrofatty-, 14 



















p-value p-value  
 Recipient characteristics  











 24.9±3.1  24.0±3.9  0.33  
Systolic blood pressure (mmHg) 107.5±18.6 66.7±13.5  
Diastolic blood pressure (mmHg) 
107.3±20.8 66.5±12.6  
 Medical history  
Hypertension (%)  4 (10)  5 (14)  0.66 0.66  
Diabetes mellitus (%)  9 (23)  4 (11)  0.16 0.16  
Left ventricular assist device (%) 9 (23)  10 (27)  0.69 0.69  
Previous smoking history (%)  21 (54)  19 (51)  0.83 0.83  
 Primary reason for HTx  
Idiopathic cardiomyopathy  30 (77)  27 (73)  0.69 0.69  
Coronary artery disease  6 (15)  5 (14)  0.82 0.82  
 Donor Characteristics  
Donor age (years)  45.7±12.3  41.4±14.0  0.16 0.16  
Female donor gender (%)  12 (31)  16 (43)  0.26 0.26  
Cold ischemia time (min)  187.5±73.2  185.3±74.7  0.91 0.91  
Recipient CMV negative/donor CMV 
positive (%) 




 Renal function and lipid profile* 
mGFR (mL/min)  61.8±15.0  64.7±14.9  0.39 0.39  
Serum creatinine (mmol/L)  103.4±31.5  99.0±29.7  0.53 0.53  
Total cholesterol (mmol/L) 3.5±2.0 3.3±1.7 0.64  
HDL (mmol/L) 0.9±0.6 0.7±0.4 0.22  
LDL (mmol/L)  2.0±1.3 2.0±1.2 0.89  
Triglycerides (mmol/L) 1.3±1.3 1.1±0.7 0.38  
Rejection episodes     
Number of patients with rejection ≥2R 
(%) within 12 months 
5 (13) 14 (38) 
0.01 
 
Number of patients with rejection ≥2R 
(%) within 36 months 
5 (13) 15 (41) 
0.01 
 
CMV infection/viremia 11 (28) 3 (8) 0.02  
Baseline IVUS     
MIT (mm) 0.45±0.18 0.44±0.19 0.82  
PAV (%) 20.1±7.0 20.2±8.0 0.94  
TAV (mm
3
) 133.2±107.9 144.6±113.1 0.66  
 2 
Data reported as mean±SD or absolute number (percentage) as appropriate.*Data at time of transplantation (V1).  3 
BMI = body mass index, LDL = low-density lipoprotein, HDL = high-density lipoprotein, mGFR = measured 4 
glomerular filtration rate, CMV = cytomegalovirus, LVAD = left ventricular assist device, MIT=maximal intimal 5 




Table 2. Regression analysis evaluating variables predicting progression of cardiac allograft 
vasculopathy at 36 months utilizing the endpoint maximal intimal thickness as a continuous 
variable. 
 
Variable  B  95% CI  β  p-value  
Recipient age  0.001  -0.002 ─ 0.003  0.06  0.61* 
Donor age  0.002  0.000 ─ 0.004  0.23  0.05  
Treatment with everolimus  -0.04  -0.10 ─ 0.01  -0.18  0.03  
Male recipient  0.07  0.007 ─ 0.13  0.29  0.03  
Diabetes mellitus -0.04  -0.11 ─ 0.04  -0.11 0.32*  
 
B=unstandardized coefficient. β =standardized coefficient 
*variables significant on univariate analysis and selected as covariates for the multivariate 




Table 3. Change in inflammatory biomarker profile from baseline to 36 months in the two 
treatment groups (n=65). 
 
Variable  Cyclosporine group  Everolimus group  p-value 
C-reactive protein (mg/L) -1.13 (-4.85 ─ 1.32)  -2.74 (-4.86 ─ 0.58)  0.92 
von Willebrand factor (AU) -4.78 (-7.35 ─ -0.12)  -2.16 (-7.34 ─ 2.26)  0.15 
Vascular cell adhesion 
molecule (ng/mL) 
-86.4 (-188.1 ─ 32.1)  -61.9 (-131.2 ─ 0.6)  0.58  
Soluble tumor-necrosis factor 
receptor-1 (pg/L) 
-0.61 (-1.34 ─ -0.12)  -0.36 (-1.21 ─ 0.14)  0.11 
Intercellular adhesion 
molecule-1(pg/L) 
-0.03 (-86.8 ─ 36.2)  -4.03 (-77.2 ─ 61.2)  0.17  
Chemokine ligand 16 (ng/mL) -0.16 (-0.56 ─ 0.18)  -0.23 (-0.59 ─ 0.12) 0.26 
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